The role of type 1 interferon in regulating alloimmune responses to transfused red blood cells

1 型干扰素在调节输注红细胞同种免疫反应中的作用

基本信息

  • 批准号:
    10194579
  • 负责人:
  • 金额:
    $ 16.41万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-07-01 至 2023-06-30
  • 项目状态:
    已结题

项目摘要

Abstract: With approximately 5 million Americans transfused per year, red blood cell (RBC) transfusion is the most common procedure performed in United States hospitals. RBC transfusion exposes recipients to hundreds of non-ABO antigens that are not matched between donors and recipients. This exposure can lead to production of antigen-specific alloantibodies, which can cause potentially fatal hemolytic transfusion reactions and limit availability of compatible blood products, resulting in anemia-associated morbidity and mortality. Currently, there are no means to predict which recipients have an elevated risk of alloimmunization. Identification of at-risk patients would allow for interventions to inhibit alloimmunization and its detrimental effects. Thus, identifying factors that determine which individuals will develop RBC alloimmune responses has been recognized as a research priority in transfusion medicine by the NHLBI. One contributing factor is the inflammatory state of the transfusion recipient. Recent studies have reported an increased frequency of alloimmunization in patients with disseminated viral infections or inflammatory diseases, including multiple autoimmune diseases. However, the molecular mechanisms underlying this association, including the role of critical inflammatory cytokines, are poorly understood. Given that type 1 interferons (IFNα/β) regulate antiviral immunity and autoimmune pathology, we hypothesize that IFNα/β signaling regulates alloimmune responses to RBC antigens. Preliminary data indicate that IFNα/β production and signaling, specifically in B cells, is required for alloimmunization in mice. Using a murine model of transfusion, we aim to identify mechanisms underlying transfusion-induced IFNα/β production (Aim 1) and B cell responses to IFNα/β signaling during RBC alloimmunization (Aim 2). Findings will provide a potential mechanistic basis for past observations of inflammation-induced alloimmunization. In addition, results may identify potential targets of laboratory tests that could improve prediction of alloimmunization. The candidate is a post-doctoral fellow in Laboratory Medicine. He proposes to gain mentored research experience and career development training as a physician-scientist in Transfusion Medicine. The project will provide experience in applying innate immune mechanisms to regulation of RBC alloimmune responses. Training will be conducted at Yale School of Medicine under the mentorship of leaders in Transfusion Medicine and innate immunity. The candidate will develop experimental and analytical skills, including microscopic analysis of lymphoid tissue, quantification of B cell processes in vivo, and acquisition and analysis of high-throughput RNA sequencing data. He will complete a career development plan that includes coursework in inflammation, biostatistics, and translational immunology. His career directions will be shaped by his participation in local and international associations of immuno-hematology research. Such training will be instrumental to the applicant's goal of generating and translating immunologic findings into improved transfusion safety as an independent investigator.
摘要: 每年约有500万美国人输血,其中以红细胞输血最多。 在美国医院中进行的常见程序。RBC输血使接受者暴露于数百例 供者和受者之间不匹配的非ABO抗原。这种接触可能会导致生产 抗原特异性同种异体抗体,这可能导致潜在的致命溶血性输血反应和限制 可获得相容的血液产品,导致贫血相关发病率和死亡率。目前,有 无法预测哪些受者的异基因免疫风险较高。风险中的识别 患者将允许采取干预措施,以抑制同种异体免疫及其有害影响。因此,识别 决定哪些人会产生RBC同种免疫反应的因素被认为是一种 NHLBI在输血医学方面的研究重点。其中一个因素是血管的炎症状态 输血接受者。最近的研究报告说,在慢性阻塞性肺疾病患者中,异基因免疫的频率增加 播散性病毒感染或炎症性疾病,包括多种自身免疫性疾病。然而, 这种联系背后的分子机制,包括关键的炎症细胞因子的作用,是 人们对此知之甚少。鉴于1型干扰素(干扰素α/β)调节抗病毒免疫和自身免疫病理, 我们假设干扰素α/β信号调节对红细胞抗原的同种异体免疫反应。初步数据 提示同种异体免疫需要干扰素α/β的产生和信号,特别是在B细胞中。 利用小鼠输血模型,我们的目标是确定输血诱导干扰素α/β的机制。 在红细胞同种异体免疫期间产生(目标1)和B细胞对干扰素α/β信号的反应(目标2)。调查结果将 为过去对炎症诱导的同种异体免疫的观察提供了潜在的机制基础。在……里面 此外,结果可能确定可能改善预测的实验室测试的潜在目标 同种异体免疫。候选人是实验室医学博士后研究员。他提议得到指导 作为输血内科医生-科学家的研究经验和职业发展培训。这个 该项目将提供将先天免疫机制应用于调节红细胞同种免疫的经验 回应。培训将在耶鲁大学医学院进行,由输血领域的领导人指导 医学和先天免疫力。应聘者将发展实验和分析技能,包括 淋巴组织的显微分析,体内B细胞过程的量化,以及采集和分析 高通量的RNA测序数据。他将完成一项职业发展计划,其中包括课程 在炎症、生物统计学和翻译免疫学方面。他的职业方向将由他的 参与当地和国际免疫血液学研究协会。这样的培训将是 有助于申请人产生免疫学发现并将其转化为改进的输血 作为一名独立调查人员的安全。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David R Gibb其他文献

Identifying Inflammatory Pathways That Promote RBC Alloimmunization in Patients with Sickle Cell Disease
  • DOI:
    10.1182/blood-2023-190681
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Rosario Hernandez-Armengol;June Young Lee;Kausik Paul;Che-Yu Chang;Tomohiro Shibata;David R Gibb
  • 通讯作者:
    David R Gibb

David R Gibb的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David R Gibb', 18)}}的其他基金

Autoantibody-induced type 1 interferons and RBC alloimmunization in sickle cell disease
镰状细胞病中自身抗体诱导的 1 型干扰素和红细胞同种免疫
  • 批准号:
    10642866
  • 财政年份:
    2022
  • 资助金额:
    $ 16.41万
  • 项目类别:
Autoantibody-induced type 1 interferons and RBC alloimmunization in sickle cell disease
镰状细胞病中自身抗体诱导的 1 型干扰素和红细胞同种免疫
  • 批准号:
    10504262
  • 财政年份:
    2022
  • 资助金额:
    $ 16.41万
  • 项目类别:
Mechanisms underlying inflammation-induced alloimmunization to RBC antigens in lupus
狼疮中炎症诱导的红细胞抗原同种免疫的机制
  • 批准号:
    10281785
  • 财政年份:
    2021
  • 资助金额:
    $ 16.41万
  • 项目类别:
Mechanisms underlying inflammation-induced alloimmunization to RBC antigens in lupus
狼疮中炎症诱导的红细胞抗原同种免疫的机制
  • 批准号:
    10458054
  • 财政年份:
    2021
  • 资助金额:
    $ 16.41万
  • 项目类别:
The role of type 1 interferon in regulating alloimmune responses to transfused red blood cells
1 型干扰素在调节输注红细胞同种免疫反应中的作用
  • 批准号:
    10445351
  • 财政年份:
    2018
  • 资助金额:
    $ 16.41万
  • 项目类别:

相似海外基金

HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
  • 批准号:
    10039902
  • 财政年份:
    2022
  • 资助金额:
    $ 16.41万
  • 项目类别:
    EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
  • 批准号:
    21K15925
  • 财政年份:
    2021
  • 资助金额:
    $ 16.41万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
  • 批准号:
    21K08410
  • 财政年份:
    2021
  • 资助金额:
    $ 16.41万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
  • 批准号:
    20K21672
  • 财政年份:
    2020
  • 资助金额:
    $ 16.41万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
  • 批准号:
    18K16395
  • 财政年份:
    2018
  • 资助金额:
    $ 16.41万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
  • 批准号:
    17K10951
  • 财政年份:
    2017
  • 资助金额:
    $ 16.41万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
  • 批准号:
    370541
  • 财政年份:
    2017
  • 资助金额:
    $ 16.41万
  • 项目类别:
    Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
  • 批准号:
    16K10863
  • 财政年份:
    2016
  • 资助金额:
    $ 16.41万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
  • 批准号:
    276706135
  • 财政年份:
    2015
  • 资助金额:
    $ 16.41万
  • 项目类别:
    Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
  • 批准号:
    15H04915
  • 财政年份:
    2015
  • 资助金额:
    $ 16.41万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了